Hunchaisri Niran, Chantapant Suprapol, Sirirattanapan Jarinratn
J Med Assoc Thai. 2015 Apr;98(4):400-7.
Investigate the benefit of zinc supplement combined with standard treatment ofidiopathic sudden sensorineural hearing loss (ISSNHL) patients.
A prospective, randomized study was designed to evaluate the hearing outcomes in ISSNHL patients treated with zinc supplement. The patients were randomized into two groups, the study and the control group. The study group received oral chelated zinc with standard treatment (oral prednisolone), while the control group received standard treatment alone. Hearing improvement was assessed from pure-tone average (PTA) and speech discrimination scores (SDS).
After treatment, significant hearing improvement was noted in both groups regarding PTA value (p = 0.016, 0.025). SDS was also improved in both groups but with no statistical significance (p > 0.05). Post-treatment PTA and SDS values between the zinc and control groups were not statistically different (p > 0.05). Hearing improvement was documented in eight of 16 patients in the study group and seven of 14 patients in the control group. This was no significant difference (p = 1.000).
Zinc supplementation does not have benefit when combined with standard treatment. Nevertheless, more subjects and well-designed studies are needed to verify the effect of zinc.
探讨补充锌剂联合特发性突发性感音神经性听力损失(ISSNHL)患者标准治疗的益处。
设计一项前瞻性随机研究,以评估补充锌剂治疗的ISSNHL患者的听力结果。将患者随机分为两组,即研究组和对照组。研究组接受口服螯合锌联合标准治疗(口服泼尼松龙),而对照组仅接受标准治疗。通过纯音平均听阈(PTA)和言语识别率(SDS)评估听力改善情况。
治疗后,两组的PTA值均有显著听力改善(p = 0.016,0.025)。两组的SDS也有所改善,但无统计学意义(p > 0.05)。锌剂组与对照组治疗后的PTA和SDS值无统计学差异(p > 0.05)。研究组16例患者中有8例听力改善,对照组14例患者中有7例听力改善。差异无统计学意义(p = 1.000)。
补充锌剂联合标准治疗并无益处。然而,需要更多受试者和设计良好的研究来验证锌的作用。